Program
Hyaluronic Acid
Also written as “sodium hyaluronate 0.18%”, “Sodium hyaluronate” and “sodium hyaluronate”.
Its studies are mostly in Dry Eye Syndromes · Osteoarthritis, Knee · Osteoarthritis · Gingivitis · Keratoconjunctivitis Sicca, led by 10 companies.
Drug pageHyaluronic Acid: every studyMany companies study it; this page follows only the 17 they lead. All 195 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laboratorios Sophia S.A de C.V.its history only | 40 open or running | phase 4since Jan 7, 2021 | Sep 4, 2019 | none ahead |
| AbbVieits history only | 30 open or running | phase 4since Sep 25, 2008 | Sep 25, 2008 | none ahead |
| Sanofiits history only | 30 open or running | phase 4since Aug 12, 2005 | Aug 12, 2005 | none ahead |
| Daiichi Sankyoits history only | 10 open or running | phase 3since May 23, 2006 | May 23, 2006 | none ahead |
| IBSA Institut Biochimiqueits history only | 11 open or running | phase 3since Sep 9, 2026 | Sep 9, 2026 | Jun 30, 2027phase 3 · NCT07819461 |
| KLSMC Stem Cellsits history only | 10 open or running | phase 2since Mar 24, 2017 | Mar 24, 2017 | none ahead |
| Kunming Baker Norton Pharmaceutical Salesits history only | 10 open or running | phase 4since Jun 27, 2016 | Jun 27, 2016 | none ahead |
| Lantibioits history only | 10 open or running | phase 3since Jan 11, 2008 | Jan 11, 2008 | none ahead |
| Liquidia Technologiesits history only | 10 open or running | phase 1since Nov 22, 2016 | Nov 22, 2016 | none ahead |
| TRB Chemedicaits history only | 10 open or running | phase 2since Dec 23, 2010 | Dec 23, 2010 | none ahead |
Also a collaborator on its studies: Premier Research Group and River Plate Biotechnology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Aug 12, 2005.
- Sep 14, 2006Phase 3 study in Osteoarthritis of ShoulderSanofi · NCT00377624 · 602 enrolled · United States
- Jan 11, 2008Lantibio’s first study: phase 3 study in Dry Eye SyndromesNew to LantibioLantibio · NCT00599716 · 300 enrolled · United States
- Sep 25, 2008AbbVie’s first study: phase 4 study in Dry Eye SyndromesNew to AbbVieAbbVie · NCT00761202 · 50 enrolled · United Kingdom
- Jan 21, 2009Phase 4 study in OsteoarthritisSanofi · NCT00830830 · 40 enrolled · United States
- Jul 10, 2009Phase 4 study in Dry Eye SyndromesAbbVie · NCT00938704 · 71 enrolled · Germany
- Dec 23, 2010TRB Chemedica’s first study: phase 2 study in Osteoarthritis, KneeNew to TRB ChemedicaTRB Chemedica · NCT01267214 · 40 enrolled · Thailand
- Apr 16, 2014Phase 4 study in Dry Eye SyndromesAbbVie · NCT02117687 · 80 enrolled · France, United Kingdom
- Jun 27, 2016Kunming Baker Norton Pharmaceutical Sales’ first study: phase 4 study in Osteoarthritis, KneeNew to Kunming Baker Norton Pharmaceutical SalesKunming Baker Norton Pharmaceutical Sales · NCT02826031 · 300 enrolled · China
- Nov 22, 2016Liquidia Technologies’ first study: phase 1 study in Acute PainNew to Liquidia TechnologiesLiquidia Technologies · NCT02982889 · 29 enrolled · Denmark
- Mar 24, 2017KLSMC Stem Cells’ first study: phase 2 study in Articular Cartilage Disorder of KneeNew to KLSMC Stem CellsKLSMC Stem Cells · NCT03101163 · 120 enrolled · United States, Malaysia
- Sep 4, 2019Laboratorios Sophia S.A de C.V.’s first study: phase 1 study in Dry Eye SyndromesNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT04081610 · 34 enrolled · Mexico
- Jan 7, 2021Phase 2 study in Dry Eye SyndromesLaboratorios Sophia S.A de C.V. · NCT04704531 · 141 enrolled · Mexico
- Jan 7, 20212 phase 4 studiesLaboratorios Sophia S.A de C.V. · NCT04704518, NCT04702776
- Sep 9, 2026IBSA Institut Biochimique’s first study: phase 3 study in Osteoarthritis, KneeNew to IBSA Institut BiochimiqueIBSA Institut Biochimique · NCT07819461 · 704 planned
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Osteoarthritis, KneeIBSA Institut Biochimique · NCT07819461
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07819461Osteoarthritis, Knee | 3 | Not yet recruiting | IBSA Institut Biochimique | Jun 30, 2027 | 704 |
| NCT04704531Dry Eye Syndromes · Mexico | 2 | Completed | Laboratorios Sophia S.A de C.V. | Jun 8, 2022 | 141 |
| NCT04704518Photorefractive Keratectomy · Mexico | 4 | Completed | Laboratorios Sophia S.A de C.V. | Dec 22, 2023 | 96 |
| NCT04702776Dry Eye Syndromes · Mexico | 4 | Completed | Laboratorios Sophia S.A de C.V. | May 15, 2023 | 182 |
| NCT04081610Dry Eye Syndromes · Mexico | 1 | Completed | Laboratorios Sophia S.A de C.V. | Oct 23, 2019 | 34 |
| NCT03101163Articular Cartilage Disorder of Knee · United States, Malaysia | 2 | Completed | KLSMC Stem Cells | Jul 2022 | 120 |
| NCT02982889Acute Pain · Denmark | 1 | Completed | Liquidia Technologies | Mar 23, 2017 | 29 |
| NCT02826031Osteoarthritis, Knee · China | 4 | UNKNOWN | Kunming Baker Norton Pharmaceutical Sales | Oct 2017 | 300 |
| NCT02117687Dry Eye Syndromes · France, United Kingdom | 4 | Completed | AbbVie | Jan 27, 2015 | 80 |
| NCT01267214Osteoarthritis, Knee · Thailand | 2 | Completed | TRB Chemedica | Feb 2010 | 40 |
| NCT00938704Dry Eye Syndromes · Germany | 4 | Completed | AbbVie | Jun 2009 | 71 |
| NCT00830830Osteoarthritis · United States | 4 | Completed | Sanofi | 40 | |
| NCT00761202Dry Eye Syndromes · United Kingdom | 4 | Completed | AbbVie | Jun 2008 | 50 |
| NCT00599716Dry Eye Syndromes · United States | 3 | Completed | Lantibio | Apr 2008 | 300 |
| NCT00377624Osteoarthritis of Shoulder · United States | 3 | Completed | Sanofi | 602 | |
| NCT00330135Osteoarthritis, Hip · France | 3 | Terminated | Daiichi Sankyo | Mar 2007 | 85 |
| NCT00130468Osteoarthritis · United States | 4 | Completed | Sanofi | 150 |
How it is read
Names in the registry
- “sodium hyaluronate 0.18%”, 2 entries
- “Sodium hyaluronate”, 2 entries
- “sodium hyaluronate”, 2 entries
- “Hyalgan (sodium hyaluronate)”, 2 entries
- “Sodium hyaluronate solution - 3.36%”, 1 entry
Codes read as this program: PRO037.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 6 studies
- Osteoarthritis, Knee, 3 studies
- Osteoarthritis, 3 studies
- Gingivitis, 1 study
- Keratoconjunctivitis Sicca, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.